Eli Lilly and Company (NYSE:LLY) Shares Purchased by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 49.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 8,294 shares of the company’s stock after purchasing an additional 2,746 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Eli Lilly and Company were worth $4,834,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Buckhead Capital Management LLC grew its stake in Eli Lilly and Company by 0.7% in the 4th quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock worth $1,226,000 after acquiring an additional 15 shares during the period. Levin Capital Strategies L.P. increased its stake in Eli Lilly and Company by 3.8% in the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after purchasing an additional 15 shares during the last quarter. JGP Wealth Management LLC lifted its position in Eli Lilly and Company by 0.9% during the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares during the period. Valley Wealth Managers Inc. boosted its stake in Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after buying an additional 17 shares during the last quarter. Finally, Sandy Cove Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 0.8% during the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after acquiring an additional 17 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $20.94 on Friday, reaching $734.97. The stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a market capitalization of $698.52 billion, a P/E ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The stock has a fifty day moving average price of $761.75 and a 200-day moving average price of $670.56.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s revenue was up 26.0% on a year-over-year basis. During the same period last year, the firm posted $1.62 EPS. Research analysts forecast that Eli Lilly and Company will post 13.83 EPS for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley lifted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. Finally, The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.